DS-1062a + Docetaxel
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Dec 21, 2020 → Jan 31, 2026
NCT ID
NCT04656652About DS-1062a + Docetaxel
DS-1062a + Docetaxel is a phase 3 stage product being developed by Daiichi Sankyo for Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04656652. Target conditions include Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04656652 | Phase 3 | Active |
Competing Products
20 competing products in Non-small Cell Lung Cancer